{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:45:39Z","timestamp":1792521939487,"version":"4.5.0"},"reference-count":127,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Connective tissue diseases (CTD) comprise a group of autoimmune diseases that can affect multiple organs in the body including the lungs. The most common form of pulmonary involvement is interstitial lung disease (ILD). CTD-associated ILD (CTD-ILD) can take one of several courses including nonprogressive, chronically progressive, or rapidly progressive. Chronically and rapidly progressive patterns are associated with increased mortality. Limited randomized controlled trial data are available for treatment of CTD-ILD, with most data coming from systemic sclerosis-related ILD. The current first-line treatment for all CTD-ILD is immunosuppression with consideration of antifibrotics, stem cell transplant, and lung transplant in progressive disease. In this article, we review data for ILD treatment options in systemic sclerosis, rheumatoid arthritis, myositis, and primary Sj\u00f6gren's syndrome-related ILDs.<\/jats:p>","DOI":"10.1055\/s-0044-1786155","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T23:20:50Z","timestamp":1715642450000},"page":"435-448","source":"Crossref","is-referenced-by-count":10,"title":["Novel Therapeutic Approaches in Connective Tissue Disease-Associated Interstitial Lung Disease"],"prefix":"10.1055","volume":"45","author":[{"given":"Erica","family":"Mulcaire-Jones","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Internal Medicine, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle Vu","family":"Pugashetti","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Internal Medicine, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Oldham","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Internal Medicine, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Internal Medicine, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00408-020-00383-w","article-title":"Connective tissue disease-related interstitial lung disease: prevalence, patterns, predictors, prognosis, and treatment","volume":"198","author":"N Jeganathan","year":"2020","journal-title":"Lung"},{"issue":"167","key":"ref2","doi-asserted-by":"crossref","first-page":"220210","DOI":"10.1183\/16000617.0210-2022","article-title":"Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis","volume":"32","author":"G M Joy","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"21","key":"ref3","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.3390\/jcm10214830","article-title":"Interstitial lung disease in connective tissue diseases: survival patterns in a population-based cohort","volume":"10","author":"C Hyldgaard","year":"2021","journal-title":"J Clin Med"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s13665-022-00290-w","article-title":"Management of connective tissue disease-related interstitial lung disease","volume":"11","author":"S Ahmed","year":"2022","journal-title":"Curr Pulmonol Rep"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","article-title":"State-of-the-art evidence in the treatment of systemic sclerosis","volume":"19","author":"J E Pope","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. an official American Thoracic Society clinical practice guideline","volume":"209","author":"G Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"09","key":"ref7","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"G Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ccm.2021.03.010","article-title":"Management of connective tissue disease-associated interstitial lung disease","volume":"42","author":"L Kawano-Dourado","year":"2021","journal-title":"Clin Chest Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"C P Denton","year":"2017","journal-title":"Lancet"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.berh.2018.08.005","article-title":"Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis","volume":"32","author":"F Ingegnoli","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","article-title":"Systemic sclerosis-associated interstitial lung disease","volume":"8","author":"A Perelas","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"A J Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"S I Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"A M Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"09","key":"ref16","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/art.34482","article-title":"A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis","volume":"64","author":"V Steen","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"D Bouros","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"04","key":"ref18","first-page":"731","article-title":"Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis","volume":"29","author":"R Giacomelli","year":"2002","journal-title":"J Rheumatol"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"R K Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"02","key":"ref20","first-page":"298","article-title":"Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease","volume":"29","author":"I Pakas","year":"2002","journal-title":"J Rheumatol"},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-132-12-200006200-00004","article-title":"Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis","volume":"132","author":"B White","year":"2000","journal-title":"Ann Intern Med"},{"issue":"25","key":"ref22","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"D P Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"09","key":"ref23","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"D P Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II","volume":"69","author":"E R Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13075-021-02548-1","article-title":"Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort","volume":"23","author":"S Jaafar","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"D Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"D Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","article-title":"Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial","volume":"205","author":"D Khanna","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"07","key":"ref29","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"S Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamadermatol.2022.6340","article-title":"Long-term outcomes after rituximab treatment for patients with systemic sclerosis: follow-up of the DESIRES trial with a focus on serum immunoglobulin levels","volume":"159","author":"A Kuzumi","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"26","key":"ref31","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"O Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"N Acharya","year":"2020","journal-title":"Rheumatol Int"},{"issue":"24","key":"ref35","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"J M van Laar","year":"2014","journal-title":"JAMA"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"K M Sullivan","year":"2018","journal-title":"N Engl J Med"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"J A Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"ref44","first-page":"vi5","article-title":"ACR\/EULAR 2010 rheumatoid arthritis classification criteria","volume":"51","author":"J Kay","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"05","key":"ref45","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1513\/pats.200703-045MS","article-title":"Rheumatoid lung disease","volume":"4","author":"K K Brown","year":"2007","journal-title":"Proc Am Thorac Soc"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"T Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","article-title":"Rheumatoid arthritis-interstitial lung disease-associated mortality","volume":"183","author":"A L Olson","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.reumae.2021.12.003","article-title":"Screening criteria for interstitial lung disease associated to rheumatoid arthritis: expert proposal based on Delphi methodology","volume":"19","author":"J Narv\u00e1ez","year":"2023","journal-title":"Reumatol Cl\u00edn (Engl Ed)"},{"issue":"11","key":"ref49","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.42162","article-title":"A risk score to detect subclinical rheumatoid arthritis-associated interstitial lung disease","volume":"74","author":"P A Juge","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1164\/rccm.201411-1950OC","article-title":"Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers","volume":"191","author":"T J Doyle","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"08","key":"ref51","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.rmed.2013.05.002","article-title":"Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD)","volume":"107","author":"J J Solomon","year":"2013","journal-title":"Respir Med"},{"issue":"02","key":"ref52","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1183\/13993003.00357-2015","article-title":"Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease","volume":"47","author":"J J Solomon","year":"2016","journal-title":"Eur Respir J"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"1800869","DOI":"10.1183\/13993003.00869-2018","article-title":"Predicting outcomes in rheumatoid arthritis related interstitial lung disease","volume":"53","author":"J Jacob","year":"2019","journal-title":"Eur Respir J"},{"issue":"04","key":"ref54","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/rheumatology\/keaa577","article-title":"Rheumatoid arthritis related interstitial lung disease - improving outcomes over 25 years: a large multicentre UK study","volume":"60","author":"C A Kelly","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"04","key":"ref55","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.chest.2022.11.035","article-title":"Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory","volume":"163","author":"S M Matson","year":"2023","journal-title":"Chest"},{"issue":"08","key":"ref56","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre","volume":"56","author":"M Y Md Yusof","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"08","key":"ref57","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/rheumatology\/kez673","article-title":"Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA registry","volume":"59","author":"C Vadillo","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"ref58","first-page":"CD007356","article-title":"Rituximab for rheumatoid arthritis","volume":"1","author":"M A Lopez-Olivo","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3899\/jrheum.091066","article-title":"Abatacept for rheumatoid arthritis: a Cochrane systematic review","volume":"37","author":"L J Maxwell","year":"2010","journal-title":"J Rheumatol"},{"issue":"12","key":"ref60","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients","volume":"59","author":"C Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"05","key":"ref61","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.semarthrit.2021.07.008","article-title":"Intravenous cyclophosphamide in acute exacerbation of rheumatoid arthritis-related interstitial lung disease: a propensity-matched analysis using a nationwide inpatient database","volume":"51","author":"K Nakamura","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"J J Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"09","key":"ref64","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study","volume":"50","author":"A Manfredi","year":"2020","journal-title":"Intern Med J"},{"issue":"03","key":"ref65","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"M Tardella","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"06","key":"ref68","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"G R Connors","year":"2010","journal-title":"Chest"},{"issue":"06","key":"ref69","doi-asserted-by":"crossref","first-page":"e98824","DOI":"10.1371\/journal.pone.0098824","article-title":"Prognostic factors for myositis-associated interstitial lung disease","volume":"9","author":"T Fujisawa","year":"2014","journal-title":"PLoS One"},{"issue":"04","key":"ref70","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/medicina57040347","article-title":"Management of myositis-associated interstitial lung disease","volume":"57","author":"T Fujisawa","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Z Chen","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"ref72","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s10067-007-0562-9","article-title":"Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study","volume":"26","author":"S Ye","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"08","key":"ref73","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.rmed.2007.02.017","article-title":"Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis","volume":"101","author":"J Won Huh","year":"2007","journal-title":"Respir Med"},{"issue":"05","key":"ref74","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease","volume":"156","author":"J A Huapaya","year":"2019","journal-title":"Chest"},{"issue":"06","key":"ref75","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"I C Mira-Avendano","year":"2013","journal-title":"Respir Med"},{"issue":"02","key":"ref76","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10067-018-4294-9","article-title":"Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy","volume":"38","author":"H Hanaoka","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"08","key":"ref77","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s10067-017-3671-0","article-title":"Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review","volume":"36","author":"R VL Koyama","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"03","key":"ref78","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00163911","article-title":"Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy","volume":"40","author":"G J Keir","year":"2012","journal-title":"Eur Respir J"},{"issue":"08","key":"ref79","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome: a retrospective case series","volume":"48","author":"M Sem","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"08","key":"ref80","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"J Bauhammer","year":"2016","journal-title":"J Rheumatol"},{"issue":"06","key":"ref81","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review","volume":"45","author":"T J Doyle","year":"2018","journal-title":"J Rheumatol"},{"issue":"10","key":"ref82","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.3390\/jcm12103406","article-title":"The efficacy and safety of rituximab in patients with idiopathic inflammatory myopathy-associated interstitial lung disease: case series","volume":"12","author":"Y Jang","year":"2023","journal-title":"J Clin Med"},{"issue":"11","key":"ref83","doi-asserted-by":"crossref","first-page":"e0133702","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, phase II trial","volume":"10","author":"Y Allenbach","year":"2015","journal-title":"PLoS One"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"820163","DOI":"10.3389\/fimmu.2021.820163","article-title":"Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review","volume":"12","author":"C He","year":"2022","journal-title":"Front Immunol"},{"issue":"06","key":"ref85","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","article-title":"Diagnosis and management of myositis-associated lung disease","volume":"163","author":"R W Hallowell","year":"2023","journal-title":"Chest"},{"issue":"01","key":"ref86","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00296-015-3328-8","article-title":"Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease","volume":"36","author":"D J Go","year":"2016","journal-title":"Rheumatol Int"},{"issue":"04","key":"ref87","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3899\/jrheum.121026","article-title":"Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease","volume":"40","author":"L Cavagna","year":"2013","journal-title":"J Rheumatol"},{"issue":"03","key":"ref88","first-page":"436","article-title":"Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease","volume":"31","author":"A Labirua-Iturburu","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","article-title":"Tacrolimus in refractory polymyositis with interstitial lung disease","volume":"353","author":"C V Oddis","year":"1999","journal-title":"Lancet"},{"issue":"05","key":"ref90","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/08916930500124023","article-title":"Polymyositis\/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants","volume":"38","author":"K Takada","year":"2005","journal-title":"Autoimmunity"},{"issue":"04","key":"ref91","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial","volume":"26","author":"T Fujisawa","year":"2021","journal-title":"Respirology"},{"issue":"09","key":"ref92","first-page":"1719","article-title":"Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis","volume":"32","author":"H Kameda","year":"2005","journal-title":"J Rheumatol"},{"issue":"03","key":"ref93","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"H Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"ref94","first-page":"952","article-title":"[Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment]","volume":"77","author":"J Hornig","year":"2018","journal-title":"Z Rheumatol"},{"issue":"37","key":"ref95","doi-asserted-by":"crossref","first-page":"e21943","DOI":"10.1097\/MD.0000000000021943","article-title":"Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: a case report","volume":"99","author":"Y Ishikawa","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1097\/RHU.0000000000000984","article-title":"Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with anti-MDA5 antibody-positive dermatomyositis","volume":"27","author":"M Kato","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"12","key":"ref97","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"K Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"07","key":"ref98","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s10067-023-06567-y","article-title":"Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis","volume":"42","author":"Y Wang","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"06","key":"ref99","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/RHU.0000000000002010","article-title":"Efficacy and safety of tofacitinib in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"29","author":"S Li","year":"2023","journal-title":"J Clin Rheumatol"},{"issue":"01","key":"ref100","doi-asserted-by":"crossref","first-page":"e002795","DOI":"10.1136\/rmdopen-2022-002795","article-title":"Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis","volume":"9","author":"T Ida","year":"2023","journal-title":"RMD Open"},{"issue":"04","key":"ref101","doi-asserted-by":"crossref","first-page":"e003599","DOI":"10.1136\/rmdopen-2023-003599","article-title":"Long-lasting improvement of refractory antisynthetase syndrome with tocilizumab: a report of two cases","volume":"9","author":"F Baumann Benvenuti","year":"2023","journal-title":"RMD Open"},{"issue":"02","key":"ref102","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/03009742.2021.1972519","article-title":"Tocilizumab and rituximab for anti-MDA-5 positive amyopathic dermatomyositis complicated with macrophage activation syndrome and progressive fibrosing interstitial lung disease","volume":"51","author":"C F Su","year":"2022","journal-title":"Scand J Rheumatol"},{"issue":"08","key":"ref103","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/CM9.0000000000001235","article-title":"Successful treatment with tocilizumab in a patient with rapidly progressive interstitial lung disease with positive anti-melanoma differentiation-associated gene-5 antibody","volume":"134","author":"F Teng","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"12","key":"ref104","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/rheumatology\/kew296","article-title":"The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome","volume":"55","author":"S M Murphy","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"33226","DOI":"10.1038\/srep33226","article-title":"Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis","volume":"6","author":"T Li","year":"2016","journal-title":"Sci Rep"},{"issue":"08","key":"ref106","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11926-023-01105-w","article-title":"Intravenous immunoglobulin in idiopathic inflammatory myopathies: a practical guide for clinical use","volume":"25","author":"P C Gandiga","year":"2023","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"ref107","first-page":"1682","article-title":"Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease","volume":"13","author":"R W Hallowell","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2019.05.012","article-title":"Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease","volume":"154","author":"J A Huapaya","year":"2019","journal-title":"Respir Med"},{"issue":"03","key":"ref109","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"187","author":"Y Suzuki","year":"2009","journal-title":"Lung"},{"issue":"02","key":"ref110","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1378\/chest.11-0492","article-title":"IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis","volume":"140","author":"E Diot","year":"2011","journal-title":"Chest"},{"issue":"02","key":"ref111","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5152\/eurjrheum.2015.0076","article-title":"High-dose intravenous immunoglobulin therapy for rapidly progressive interstitial pneumonitis accompanied by anti-melanoma differentiation-associated gene 5 antibody-positive amyopathic dermatomyositis","volume":"2","author":"K Hamada-Ode","year":"2015","journal-title":"Eur J Rheumatol"},{"issue":"09","key":"ref112","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1093\/rheumatology\/keab928","article-title":"Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"61","author":"L M Wang","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"02","key":"ref113","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1378\/chest.10-0360","article-title":"Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin","volume":"139","author":"C J Bakewell","year":"2011","journal-title":"Chest"},{"issue":"23","key":"ref114","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.2169\/internalmedicine.1121-18","article-title":"Anti-MDA5 antibody-positive dermatomyositis complicated by autoimmune-associated hemophagocytic syndrome that was successfully treated with immunosuppressive therapy and plasmapheresis","volume":"57","author":"Y Fujita","year":"2018","journal-title":"Intern Med"},{"issue":"01","key":"ref115","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/24725625.2020.1826641","article-title":"Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease","volume":"5","author":"N Sasaki","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"issue":"11","key":"ref116","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"M Shirakashi","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"01","key":"ref119","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sj\u00f6gren's syndrome: a systemic autoimmune disease","volume":"22","author":"S Negrini","year":"2022","journal-title":"Clin Exp Med"},{"key":"ref120","first-page":"291","article-title":"Interstitial lung disease in Sjogren's syndrome: a clinical review","volume":"38","author":"F Luppi","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"02","key":"ref121","doi-asserted-by":"crossref","first-page":"102447","DOI":"10.1016\/j.autrev.2019.102447","article-title":"Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sj\u04e7gren's syndrome: a systematic review from the Italian Society of Rheumatology","volume":"19","author":"G Sambataro","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"01","key":"ref122","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/rheumatology\/kes311","article-title":"Clinical pulmonary involvement in primary Sjogren's syndrome: prevalence, quality of life and mortality\u2013a retrospective study based on registry data","volume":"52","author":"O Palm","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"ref123","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/rheumatology\/kev200","article-title":"Characterization of systemic disease in primary Sj\u00f6gren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements","volume":"54","author":"M Ramos-Casals","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"ref124","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1007\/s10067-018-4289-6","article-title":"A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sj\u00f6gren's syndrome-related interstitial lung disease in a Chinese population","volume":"37","author":"X Dong","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"01","key":"ref125","doi-asserted-by":"crossref","first-page":"e000022","DOI":"10.1136\/rmdopen-2014-000022","article-title":"EULAR Sj\u00f6gren's syndrome disease activity index (ESSDAI): a user guide","volume":"1","author":"R Seror","year":"2015","journal-title":"RMD Open"},{"issue":"06","key":"ref126","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren's syndrome patient reported index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome","volume":"70","author":"R Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"02","key":"ref127","first-page":"136","article-title":"Treatment of primary Sj\u00f6gren's syndrome-related interstitial lung disease: a retrospective cohort study","volume":"37","author":"B Amlani","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"01","key":"ref128","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.autrev.2016.09.017","article-title":"Interstitial lung disease in primary Sj\u00f6gren's syndrome","volume":"16","author":"F Roca","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"08","key":"ref129","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41584-021-00634-x","article-title":"Current and future therapies for primary Sj\u00f6gren syndrome","volume":"17","author":"R Seror","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"02","key":"ref130","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","article-title":"Improvement of Sj\u00f6gren's syndrome after two infusions of rituximab (anti-CD20)","volume":"57","author":"V Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"06","key":"ref131","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry","volume":"72","author":"J E Gottenberg","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"06","key":"ref132","first-page":"1077","article-title":"Rituximab therapy in primary Sj\u00f6gren's syndrome with interstitial lung disease: a retrospective cohort study","volume":"34","author":"M H Chen","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"05","key":"ref133","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"A Fischer","year":"2013","journal-title":"J Rheumatol"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","article-title":"Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease","volume":"121","author":"J M Oldham","year":"2016","journal-title":"Respir Med"},{"issue":"01","key":"ref135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial","volume":"18","author":"P Saunders","year":"2017","journal-title":"Trials"},{"issue":"06","key":"ref136","doi-asserted-by":"crossref","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"J Mankikian","year":"2023","journal-title":"Eur Respir J"},{"issue":"18","key":"ref137","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"K R Flaherty","year":"2019","journal-title":"N Engl J Med"},{"issue":"06","key":"ref138","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.42075","article-title":"Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial","volume":"74","author":"E L Matteson","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"05","key":"ref139","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"J Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"871861","DOI":"10.3389\/fmed.2022.871861","article-title":"The efficacy and safety of pirfenidone combined with immunosuppressant therapy in connective tissue disease-associated interstitial lung disease: a 24-week prospective controlled cohort study","volume":"9","author":"J Wang","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"08","key":"ref141","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"F M\u00fcller","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1786155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:39:23Z","timestamp":1730803163000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1786155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":127,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,5,22]]},"published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1786155","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]}}}